tbuckley/cabot-search huggingface dataset:
TCT-369 Efficacy and Safety of Figure-of-Eight Suture Versus Manual Pressure for Venous Access Closure: A Meta-Analysis
Authors: Varunsiri Atti, Aakash Angirekula, Mohit Turagam, Poonam Velagapudi, Kuladeep Gidda, Smit Patel, Mark Terence Mujer, Nileshkumar Patel, Supratik Rayamajhi, Dhanunjaya Lakkireddy
Journal: Journal of the American College of Cardiology (2019)
TCT-69 A Prospective, Multicenter, Randomized Study to Evaluate the Optimal Strategy for Side Branch Treatment in Patients With Left Main Coronary Bifurcation Lesion (SMART-STRATEGY II)
Authors: Kim Jihoon, Young Bin Song, Joo Myung Lee, Taek Kyu Park, Jeong Hoon Yang, Joo-Yong Hahn, Jin-Ho Choi, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Seung-Woon Rha, June-Hong Kim, Woojung Chun, Hyo-Soo Kim, Jong-Seon Park, Sung Yun Lee, Myung Ho Jeong, Jae-Hwan Lee
Journal: Journal of the American College of Cardiology (2019)
Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study
Authors: Charlotte Maggen, Daan Dierickx, Pieternella Lugtenburg, Annouschka Laenen, Elyce Cardonick, Roman G Smakov, Mar Bellido, Alvaro Cabrera-Garcia, Mina Mhallem Gziri, Michael J Halaska, Petronella B Ottevanger, Kristel Van Calsteren, Andie O'Laughlin, Evgeniya Polushkina, Laura Van Dam, Irit Avivi, Peter Vandenberghe, F J Sherida H Woei-A-Jin, Frédéric Amant
Journal: The Lancet Haematology (2019)
Neutrophil Extracellular Traps Exacerbate Inflammatory Responses and Thrombotic Tendency in Both a Murine Colitis Model and Patients with Inflammatory Bowel Disease
Authors: Muhua Cao, Muxin Yu, Yan Zhang, Dongxia Tong, Li Guo, Chunxu Wang, Tao Li, Xiaoyan Yang, Cong Zhang, Junjie Kou, Yayan Bi, Jin Zhou, Jialan Shi
Journal: Blood (2017)
Reply to Yang et al.
Authors: Liansong Ye, Jingsun Jiang, Bing Hu
Journal: Endoscopy (2019)

See also:Tips and tricks for avoiding the dreaded intramural esophageal dissection during peroral endoscopic myotomy: recognize!Endoscopy 2019; 51(10): 996-996DOI: 10.1055/a-0958-2395
TCT-152 Use of the PRECISE-DAPT Score to Predict Mortality in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Authors: Anum Asif, Ahmet Sezer, Floyd Thoma, Catalin Toma, John Schindler, Jeffrey Fowler, Oscar Marroquin, A.J. Conrad Smith, Suresh Mulukutla
Journal: Journal of the American College of Cardiology (2019)
TCT-472 Distribution of Coronary Flow Capacity Is Different Among the Groups by Abnormal CFR/HMR in Nonobstructive Coronary Artery Disease Patients
Authors: Jin-Sin Koh, Arnav Kumar, Parham Eshtehardi, Sonali Kumar, Sonu Gupta, Nabil Sabbak, Habib Samady
Journal: Journal of the American College of Cardiology (2019)
Clinical Approach to Lactose Intolerance
Authors: Dejan Micic, Vijaya L. Rao, David T. Rubin
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TCT-64 Intravascular Molecular-Structural Imaging of Arterial Permeability and Vascular Injury In Vivo: Implications for Drug-Coated Balloon Efficacy
Authors: Mazen Albaghdadi, Zhonglie Piao, Mohammed Chowdhury, Eric Osborn, Adam Mauskapf, Osman Ahsen, Abraham Tzafriri, Elazer Edelman, Guillermo Tearney, Farouc Amin Jaffer
Journal: Journal of the American College of Cardiology (2019)
Cost-Effectiveness of Transcatheter Mitral Valve Repair Versus Medical Therapy in Patients With Heart Failure and Secondary Mitral Regurgitation
Authors: Suzanne J. Baron, Kaijun Wang, Suzanne V. Arnold, Elizabeth A. Magnuson, Brian Whisenant, Andreas Brieke, Michael Rinaldi, Anita W. Asgar, Joann Lindenfeld, William T. Abraham, Michael J. Mack, Gregg W. Stone, David J. Cohen
Journal: Circulation (2019)

The COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) demonstrated that edge-to-edge transcatheter mitral valve repair (TMVr) with the MitraClip resulted in reduced mortality and heart failure hospitalizations and improved quality of life compared with maximally tolerated guideline-directed medical therapy (GDMT) in patients with heart failure and 3 to 4+ secondary mitral regurgitation. Whether TMVr is cost-effective compared with GDMT in this population is unknown. We used data from the COAPT trial to perform a formal patient-level economic analysis of TMVr+GDMT versus GDMT alone for patients with heart failure and 3 to 4+ secondary mitral regurgitation from the perspective of the US healthcare system. Costs for the index TMVr hospitalization were assessed using a combination of resource-based accounting and hospital billing data (when available). Follow-up medical care costs were estimated on the basis of medical resource use collected during the COAPT trial. Health utilities were estimated for all patients at baseline and 1, 6, 12, and 24 months with the Short Form Six-Dimension Health Survey. Initial costs for the TMVr procedure and index hospitalization were $35 755 and $48 198, respectively. Although follow-up costs were significantly lower with TMVr compared with GDMT ($26 654 versus $38 345; P=0.018), cumulative 2-year costs remained higher with TMVr because of the upfront cost of the index procedure ($73 416 versus $38 345; P<0.001). When in-trial survival, health utilities, and costs were modeled over a lifetime horizon, TMVr was projected to increase life expectancy by 1.13 years and quality-adjusted life-years by 0.82 years at a cost of $45 648, yielding a lifetime incremental cost-effectiveness ratio of $40 361 per life-year gained and $55 600 per quality-adjusted life-year gained. For symptomatic patients with heart failure and 3 to 4+ secondary mitral regurgitation, TMVr increases life expectancy and quality-adjusted life expectancy compared with GDMT at an incremental cost per quality-adjusted life-year gained that represents acceptable economic value according to current US thresholds. URL: https://www.clinicaltrials.gov. Unique identifier: NCT01626079.
Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis
Authors: Benjamin Ng, Jinrui Dong, Giuseppe D’Agostino, Sivakumar Viswanathan, Anissa A. Widjaja, Wei-Wen Lim, Nicole S. J. Ko, Jessie Tan, Sonia P. Chothani, Benjamin Huang, Chen Xie, Chee Jian Pua, Ann-Marie Chacko, Nuno Guimarães-Camboa, Sylvia M. Evans, Adam J. Byrne, Toby M. Maher, Jiurong Liang, Dianhua Jiang, Paul W. Noble, Sebastian Schafer, Stuart A. Cook
Journal: Science Translational Medicine (2019)

Interleukin-11 is important for lung fibroblast activation in idiopathic pulmonary fibrosis, and its signaling represents a therapeutic target.
TCT-719 Antithrombotic Strategies After Transcatheter Aortic Valve Implantation: Insights From a Network Meta-Analysis
Authors: Toshiki Kuno, Hisato Takagi, Takehiro Sugiyama, Tomo Ando, Satoshi Miyashita, Nelson Valentin, Shimada Yuichi, Masaki Kodaira, Yohei Numasawa, Yumiko Kanei, Kentaro Hayashida, Sripal Bangalore
Journal: Journal of the American College of Cardiology (2019)
TCT-583 Predictors of Functional Significance of Coronary Bifurcation Stenoses—Importance of Lesion Characteristics and SYNTAX Score: Analysis From FIESTA Registry Database (NCT01724957)
Authors: Dobrin Vassilev, Niya Mileva, Pavel Nikolov, Georgi Dimitrov, Kiril Karamfiloff, Carlos Collet, Bon-Kwon Koo, Robert Gil, Patrick Serruys
Journal: Journal of the American College of Cardiology (2019)
TCT-496 Impact of Body Mass Index on Infarct Size and Clinical Outcomes Following Primary PCI: Patient-Level Analysis From 6 Randomized Trials
Authors: Bahira Shahim, Shmuel Chen, Bjorn Redfors, Holger Thiele, Ingo Eitel, Fotios Gkargkoulas, Aaron Crowley, Akiko Maehara, Ori Ben-Yehuda, Gregg Stone
Journal: Journal of the American College of Cardiology (2019)
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial
Authors: Gianni Bisogno, Gian Luca De Salvo, Christophe Bergeron, Soledad Gallego Melcón, Johannes H Merks, Anna Kelsey, Helene Martelli, Veronique Minard-Colin, Daniel Orbach, Heidi Glosli, Julia Chisholm, Michela Casanova, Ilaria Zanetti, Christine Devalck, Myriam Ben-Arush, Peter Mudry, Sima Ferman, Meriel Jenney, Andrea Ferrari
Journal: The Lancet Oncology (2019)
TCT-701 Pulmonary Hypertension With Elevated Pulmonary Vascular Resistance Is Associated With Long-Term Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement
Authors: Ibrahim Sultan, Miho Fukui, Valentino Bianco, Dustin Kliner, Floyd Thoma, John Schindler, Thomas Gleason, Joao Cavalcante
Journal: Journal of the American College of Cardiology (2019)
Atopic eczema and fracture risk in adults: A population-based cohort study
Authors: Katherine E. Lowe, Kathryn E. Mansfield, Antonella Delmestri, Liam Smeeth, Amanda Roberts, Katrina Abuabara, Daniel Prieto-Alhambra, Sinéad M. Langan
Journal: Journal of Allergy and Clinical Immunology (2019)

Limited evidence suggests increased fracture risk in people with atopic eczema. Any link could have substantial effect; atopic eczema is common, and fractures have associated morbidity and mortality.
Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes
Authors: Mariusz Tomaniak, Ply Chichareon, Yoshinobu Onuma, Efthymios N. Deliargyris, Kuniaki Takahashi, Norihiro Kogame, Rodrigo Modolo, Chun Ching Chang, Tessa Rademaker-Havinga, Robert F. Storey, George D. Dangas, Deepak L. Bhatt, Dominick J. Angiolillo, Christian Hamm, Marco Valgimigli, Stephan Windecker, Philippe Gabriel Steg, Pascal Vranckx, Patrick W. Serruys
Journal: JAMA Cardiology (2019)

<h3>Importance</h3> The role of aspirin as part of antiplatelet regimens in acute coronary syndromes (ACS) needs to be clarified in the context of newer potent P2Y12 antagonists. <h3>Objective</h3> To evaluate the benefit and risks of aspirin in addition to ticagrelor among patients with ACS beyond 1 month after percutaneous coronary intervention (PCI). <h3>Design, Setting, and Participants</h3> This is a nonprespecified, post hoc analysis of GLOBAL LEADERS, a randomized, open-label superiority trial comparing 2 antiplatelet treatment strategies after PCI. The trial included 130 secondary/tertiary care hospitals in different countries, with 15 991 unselected patients with stable coronary artery disease or ACS undergoing PCI. Patients had outpatient visits at 1, 3, 6, 12, 18, and 24 months after index procedure. <h3>Interventions</h3> The experimental group received aspirin plus ticagrelor for 1 month followed by 23-month ticagrelor monotherapy; the reference group received aspirin plus either clopidogrel (stable coronary artery disease) or ticagrelor (ACS) for 12 months, followed by 12-month aspirin monotherapy. In this analysis, we examined the clinical outcomes occurring between 31 days and 365 days after randomization, specifically in patients with ACS who, within this time frame, were assigned to receive either ticagrelor alone or ticagrelor and aspirin. <h3>Main Outcomes and Measures</h3> The primary outcome was the composite of all-cause death or new Q-wave myocardial infarction. <h3>Results</h3> Of 15 968 participants, there were 7487 patients with ACS enrolled; 3750 patients were assigned to the experimental group and 3737 patients to the reference group. Between 31 and 365 days after randomization, the primary outcome occurred in 55 patients (1.5%) in the experimental group and in 75 patients (2.0%) in the reference group (hazard ratio [HR], 0.73; 95% CI, 0.51-1.03;<i>P</i> = .07); investigator-reported Bleeding Academic Research Consortium–defined bleeding type 3 or 5 occurred in 28 patients (0.8%) in the experimental group and in 54 patients (1.5%) in the reference arm (HR, 0.52; 95% CI, 0.33-0.81;<i>P</i> = .004). <h3>Conclusions and Relevance</h3> Between 1 month and 12 months after PCI in ACS, aspirin was associated with increased bleeding risk and appeared not to add to the benefit of ticagrelor on ischemic events. These findings should be interpreted as exploratory and hypothesis generating; however, they pave the way for further trials evaluating aspirin-free antiplatelet strategies after PCI. <h3>Trial Registration</h3> ClinicalTrials.gov identifier:NCT01813435.
Airway obstruction in young adults born extremely preterm or extremely low birth weight in the postsurfactant era
Authors: Lex William Doyle, Louis Irving, Anjali Haikerwal, Katherine Lee, Sarath Ranganathan, Jeanie Cheong
Journal: Thorax (2019)

Background It is unknown if adults born &lt;28 weeks or &lt;1000 g since surfactant has been available are reaching their full airway growth potential. Objective To compare expiratory airflow at 25 years and from 8 to 25 years of participants born &lt;28 weeks or &lt;1000 g with controls, and within the preterm group to compare those who had bronchopulmonary dysplasia with those who did not. Methods All survivors born &lt;28 weeks or &lt;1000 g in 1991–1992 in Victoria, Australia, were eligible. Controls were born contemporaneously, weighing &gt;2499 g. At 8, 18 and 25 years, expiratory airflows were measured and the results converted to z-scores. Outcomes were compared between groups at age 25 years, and trajectories (change in z-scores per year) from childhood were contrasted between groups. Results Expiratory airflows were measured at 25 years on 164 of 297 (55%) preterm survivors and 130 of 260 (50%) controls. Preterm participants had substantially reduced airflow compared with controls at age 25 years (eg, zFEV 1 ; mean difference −0.97, 95% CI −1.23 to –0.71; p&lt;0.001). Preterm participants had lower airflow trajectories than controls between 8 and 18 years, but not between 18 and 25 years. Within the preterm group, those who had bronchopulmonary dysplasia had worse airflows and trajectories than those who did not. Conclusions Young adults born &lt;28 weeks or &lt;1000 g in the surfactant era, particularly those who had bronchopulmonary dysplasia, have substantially reduced airway function compared with controls. Some are destined to develop COPD in later adult life.
Bioresorbable Scaffolds
Authors: Lorenz Räber, Yasushi Ueki
Journal: Circulation (2019)

Bioresorbable scaffolds (BRSs) were designed to reduce adverse events related to permanent metallic stents by providing temporal mechanical support and subsequent complete resorption.The BRS hypothesis was built on the assumption that the absence of metallic caging would facilitate full restoration of vasomotion, induce luminal enlargement and plaque burden reduction, and, most important, mitigate lesion-related events compared with permanent metallic drug-eluting stents (DESs).Although a total of 8 BRSs have entered clinical evaluation, the Absorb BVS is the only one that was extensively tested.A decade ago, Ormiston et al 1 reported the results of the first-in-human ABSORB cohort A study using the Absorb BVS 1.0 polymeric BRSs.Reinforcement of the mechanical performance and prolongation of its mechanical integrity for a longer period of time led to second-generation Absorb BVS 1.1, which was approved in Europe in 2011 and subsequently in the United States in 2016.To date, the Absorb BVS has been compared with newer generation metallic everolimus-eluting stents in ≈10 000 patients from 9 randomized controlled trials covering a wide range of patient subsets (ie, all-comer population, 2 ST-segment-elevation myocardial infarction [STEMI], 3 complex lesions 4 ).The initial expectation of being on par with metallic DES before complete degradation was not fulfilled.A detailed patient-level synthesis including 3389 study participants with follow-up of 3 years (ie, before complete degradation) reported an increased risk of target vessel myocardial infarction and target lesion revascularization (TLR) and concerning hazards of device thrombosis occurring early and late after device implantation. 5These findings were confirmed by a large all-comers trial at a follow-up of 3 years. 2Although the risk of TLR was subsequently much improved by a rigorous implementation of all the lessons learned (eg, avoiding small vessels and applying BVS-specific implantation protocols with routine predilatation and postdilatation) in the ABSORB IV trial 6 and the COMPARE-ABSORB trial 4 (ABSORB Bioresorbable Scaffold vs Xience Metallic Stent for Prevention of Restenosis in Patients at High Risk of Restenosis), the concerns about device thrombosis continued.It is disappointing that other prophecies beyond the failed mitigation of device-related events could not be confirmed.Vasoreactivity was not different between Absorb BVS and the metallic counterpart at 3 years, 7 and in the same study, late lumen enlargement was limited to 25% of lesions 8 and to 6.4% in the ABSORB Japan trial. 9he increased hazards for device thrombosis are attributable to various BVSspecific properties, including less radial force, expansion limits, thicker struts, limited biocompatibility of poly-l-lactic acid and the extensive time until degradation, leading to new resorption-related failure mechanisms such as scaffold dismantling (Figure). 10,11
TCT-758 Assessment of Bioprosthetic Valve Leaflet Displacement During Valve-in-Valve TAVI; an Ex-Vivo Bench Study
Authors: Mark Hensey, Janarthanan Sathananthan, Stephanie Sellers, Althea Lai, Uri Landes, Abdullah Alkhodair, Anson Cheung, Philipp Blanke, Jonathon Leipsic, David Wood, Jian Ye, John Webb
Journal: Journal of the American College of Cardiology (2019)
Hypophosphataemia in acute liver failure.
Authors: D J Dawson, C Babbs, T W Warnes, R H Neary
Journal: BMJ (1987)

13 observations d'insuffisance hepatique aigue avec coma (12 cas dus au paracetamol, 1 a une hepatite virale non A-NON-B). Hypophosphatemie dans tous les cas. Correlation entre le degre d'hypophosphatemie et l'evolution. 6 des malades sont morts
TCT-57 Plantar Thermography in Predicting Wound Healing in Patients With Critical Limb Ischemia
Authors: Wei-chun Chang, Yutsung Jeng, ChiYen Wang, Yu-Po Hung, Tzu-shiang Lin, Wei Chen, Chieh-Shou Su, Wen-Lieng Lee
Journal: Journal of the American College of Cardiology (2019)
TCT-384 Is Higher Operator Volumes for Unprotected Left Main Stem PCI Associated With Improved Patient Outcomes? A Survival Analysis of 6,748 Cases From the British Cardiovascular Intervention Society National Database
Authors: Tim Kinnaird, Sean Gallagher, Richard Anderson, Andrew Sharp, Peter Ludman, Samuel Copt, Adrian Banning, Mamas Mamas, Nick Curzen
Journal: Journal of the American College of Cardiology (2019)
TCT-214 Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Chronic Total Coronary Occlusions: A Systematic Review and Meta-Analysis of Randomized Trials
Authors: Anna van Veelen, Joelle Elias, Ivo M. van Dongen, Bimmer Claessen, Jose P.S. Henriques
Journal: Journal of the American College of Cardiology (2019)
TCT-686 The Impact of Coronary Artery Disease and Pre-Procedural PCI on the Short- and Long-Term Mortality After TAVR
Authors: Thomas van den Boogert, Jetske Gunster, Martijn van Mourik, Jeroen Vendrik, Bimmer Claessen, Floortje van Kesteren, Karel Koch, Joanna Wykrzykowska, M. Marije Vis, M. Beijk, Robbert de Winter, Nils Planken, Jan Baan, Jose P.S. Henriques
Journal: Journal of the American College of Cardiology (2019)
TCT-628 Long-Term Outcomes After Percutaneous Coronary Intervention Relative to Bypass Surgery in Diabetic Patients With Multivessel Coronary Artery Disease According to Clinical Presentation
Authors: Yong-Joon Lee, Sung-Jin Hong, Byeong-Keuk Kim, Sanghoon Shin, Yongsung Suh, Seunghwan Kim, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang
Journal: Journal of the American College of Cardiology (2019)
Registrar who left emergency department while pregnant woman was in cardiac arrest is struck off after showing no “convincing remorse”
Authors: Clare Dyer
Journal: BMJ (2019)

A locum registrar in obstetrics and gynaecology who left the emergency department while a pregnant patient was in cardiac arrest has been struck off the UK medical register after failing for a third time to convince a tribunal of his remorse.

A medical practitioners tribunal in 2017 found that Frederick Makoha had failed to respond in time to the patient’s symptoms or to perform an adequate examination. He had also failed to consult colleagues, to remain in the resuscitation room to support cardiopulmonary resuscitation, to provide effective treatments based on the best available evidence, or to take all possible steps to alleviate pain and distress.

The 37 year old patient, who had conceived through in vitro fertilisation and had a known history …
TCT-155 In-Hospital Outcomes and Trends of Limb Revascularization Procedures in Patients With and Without Atrial Fibrillation
Authors: Homam Moussa Pacha, Yasser Al-khadra, Fahed Darmoch, Mohamad Soud, Anwar Zaitoun, Chun Shing Kwok, Mamas Mamas, Amir Kaki, Santiago Garcia, Subhash Banerjee, Salman Arain, George Vetrovec, James Glazier, Babar Basir, Rajiv Tayal, M. Chadi Alraies
Journal: Journal of the American College of Cardiology (2019)